Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cardiovascular manifestations secondary to COVID-19: A narrative review

C. Fauvel, A. Trimaillé, O. Weizman, T. Pezel, D. Mika, V. Waldmann, A. Cohen, G. Bonnet

ARTICLE INFO

Article History:
Received 20 December 2021
Revised 1 March 2022
Accepted 8 March 2022
Available online 4 May 2022

Keywords:
COVID-19
Cardiovascular system

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has spread rapidly, becoming a major threat to global health. In addition to having required the adaptation of healthcare workers for almost 2 years, it has been much talked about, both in the media and among the scientific community. Beyond lung damage and respiratory symptoms, the involvement of the cardiovascular system largely explains COVID-19 morbimortality. In this review, we emphasize that cardiovascular involvement is common and is associated with a worse prognosis, and that earlier detection by physicians should lead to better management. First, direct cardiac involvement will be discussed, in the form of COVID-19 myocarditis, then secondary cardiac involvement, such as myocardial injury, myocardial infarction and arrhythmias, will be considered. Finally, worsening of previous cardiovascular disease as a result of COVID-19 will be examined, as well as long-term COVID-19 effects and cardiovascular complications of COVID-19 vaccines.

© 2022 SPLF and Elsevier Masson SAS. All rights reserved.

1. Introduction

Since the end of 2019, the world has been facing a pandemic of unprecedented magnitude, caused by a new membrane-enveloped positive-sense single-stranded ribonucleic acid virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From the Chinese epicenter, the pandemic has spread rapidly, and is now evolving in successive waves of varying intensity, becoming a major threat to global health [1,2]. By the end of 2021, an estimated five million people will have died from this pandemic, including about 115,000 healthcare workers worldwide [2].

Coronavirus disease 2019 (COVID-19) usually manifests as respiratory symptoms of varying gravity, ranging from totally asymptomatic forms or “flu-like syndrome” with anosmia, to acute respiratory distress syndrome, requiring admission to an intensive care unit and mechanical ventilation [3]. Despite the pulmonary tropism of the virus, many studies have emphasized the complex interplay between the cardiovascular system and SARS-CoV-2. First, descriptive works have shown that cardiac symptoms, such as chest pain or palpitations, are frequently at the forefront of the clinical presentation [1,4,5]. Second, COVID-19 is potentially the cause of a wide range of cardiovascular complications with different inflammatory and thrombotic pathomechanisms [6–8]. Finally, previous cardiac comorbidities and cardiovascular risk factors are frequent in patients hospitalized with COVID-19, and negatively impact the prognosis [9–11].

Thus, our aim was to review the available data on the impact of COVID-19 on the cardiovascular system, to alert physicians to its importance in explaining the morbimortality of the disease and to
extract key messages for daily clinical practice. According to pathophysiology, the acute cardiovascular manifestations can be divided into three categories: (1) primary cardiac involvement; (2) secondary cardiac involvement; and (3) worsening of previous cardiovascular diseases. Finally, we address long-term cardiovascular complications, as well as vaccine-related consequences of COVID-19. We also provide tables summarizing the prognostic and/or diagnostic value of cardiac multimodality imaging and biomarkers in this context (Tables 1 and 2, Fig. 1).

2. Primary cardiac involvement

Cardiac involvement in COVID-19 is directly connected to SARS-CoV-2 pathophysiology. Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound enzyme that degrades angiotensin II to angiotensin-(1-7), resulting in vasodilator, antifibrotic and antiapoptotic effects [12-14]. This wide range of expression of ACE2 probably explains, at least in part, the pathophysiology of COVID-19 myocarditis.

Indeed, from the beginning of the pandemic, several case series have reported SARS-CoV-2-induced myocarditis with varying degrees of severity, sometimes leading to cardiogenic shock [15-21]. Most of these cases were only based on the association of a clinical context (i.e. confirmed SARS-CoV-2 infection and/or the presence of typical chest pain and/or dyspnea), troponin concentration increase and updated cardiac magnetic resonance (CMR) recommendations (Lake Louise Criteria) [22]. However, according to the position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, the gold standard for the diagnosis of definite myocarditis is endomyocardial biopsy [23], so direct evidence of SARS-CoV-2 damage to cardiomyocytes remains limited. In 39 consecutive autopsies from Germany, Lindner et al. demonstrated that 16 of 39 cases (41%) had more than 1000 copy numbers of the virus (1000 viral copies) into the myocardium, but without myocarditis as defined by the Dallas Criteria [23,24]. Another autopsy case study showed that the

| Table 1 | Cardiovascular manifestations secondary to COVID-19: The value of multimodality imaging. |
|---------|-------------------------------------------------------------------------------------|
| Echocardiography | CMR | Chest tomography | CTA | General considerations |
| Myocarditis | If clinical suspicion; assess LV function and kinetic abnormalities | Positive diagnosis (Lake Louise Criteria) | Rule out coronary artery disease | Endomyocardial biopsy should not be performed routinely |
| Myocardial injury | | | | |
| MI | Assess biventricular function; search for acute complications (i.e. mitral regurgitation, ventricular septal defect) | | | The central issue is the timing of revascularization while minimizing infectious risks for the healthcare team |
| Pulmonary embolism | Not performed routinely in COVID-19 context; in case of hemodynamic instability, to rule out cardiogenic shock | Certainty of diagnosis: CTPA | | CTPA is not always recommended for patients with COVID-19, but should be performed in case of suspicion or in the presence of risk factors |
| Right heart failure | Prognostic value of RV dysfunction and dilatation | If pulmonary embolism is suspected | | Right heart failure should not be routinely considered by physicians; however, if echocardiography has been requested for another reason, its presence is associated with worse outcome |
| Chronic heart failure decompensation | Certainty of diagnosis; etiology of acute heart failure | Should not be performed routinely | | All four exams may be of value, but not in the COVID-19 context |

Under normal circumstances, each exam may be of value, but in the COVID-19 pandemic, physicians have to deal with diagnostic efficiency and minimize the infectious risk for the healthcare team. CCTA: coronary computed tomography angiography; CMR: cardiac magnetic resonance; COVID-19: coronavirus disease 2019; CTPA: chest tomography pulmonary angiogram; LV: left ventricular; MI: myocardial infarction; RV: right ventricular.

Remains a priority in patients with COVID-19.

Not always a priority in patients with COVID-19.

Little value in patients with COVID-19.

| Table 2 | Cardiovascular manifestations secondary to COVID-19: The role of biological findings. |
|---------|-------------------------------------------------------------------------------------|
| Natriuretic peptides (BNP or NT-proBNP) | Troponin |
| Prognostic value | Positive diagnosis | Prognostic value | Positive diagnosis |
| Myocarditis | X | | X |
| Myocardial injury | | X | | X |
| Myocardial infarction | X | | X |
| Pulmonary embolism | X | | X |
| Right heart failure | X | X | |
| Chronic heart failure decompensation | X | X | |

BNP: brain natriuretic peptide; COVID-19: coronavirus disease 2019; NT-proBNP: N-terminal prohormone of brain natriuretic peptide.
The virus can enter directly into endothelial heart cells, suggesting another potential mechanism for primary cardiac involvement [25]. In a systematic review, Kawakami et al. showed that myocarditis was uncommon in autopsies or endomyocardial biopsies; indeed, histologic evidence of myocarditis caused by SARS-CoV-2 was only found in about 4.5% of cases [26]. Finally, a larger autopsy cohort, including 277 subjects so far, has shown that COVID-19 related myocarditis occurs at a rate between 1.4 and 7.2% [27]. Finally, facing these scarce data, it remains difficult to state that myocarditis observed among COVID-19 patients is primarily related to a direct viral effect on the myocardium rather than a systemic inflammatory response and cytokine storm. Thus, it may be more appropriate to refer to "COVID-19-associated myocarditis" rather than "myocarditis related to COVID-19".

In the clinical cases and cohorts mentioned previously, there were no clinical, biological or multimodality imaging specificities that allowed a diagnosis of COVID-19-associated myocarditis rather than myocarditis with another cause. Although myocarditis can present with varying degrees of clinical severity, ranging from mild symptoms to cardiac arrest as a result of ventricular arrhythmia and/or cardiogenic shock, the typical presentation combines acute chest pain with ST/T wave changes on the electrocardiogram (i.e. ST-segment elevation or depression or T wave inversions), with an increased cardiac troponin concentration, in the absence of angio- graphic evidence of coronary artery disease [23].

Regarding the use of endomyocardial biopsy to confirm the diagnosis, although specific recommendations in the context of COVID-19 have not been issued, it seems unreasonable to suggest this at-risk procedure for routine practice. An endomyocardial biopsy involves risks, albeit low (i.e. 0.03% risk of death, 1.2% risk of heart perforation) [28], its diagnostic yield is low and in the majority of cases it will not change management, as there are no proven effective treatments [26]. COVID-19-associated myocarditis mainly seems to concern young patients [29]. With methodological caution secondary to the absence of endomyocardial biopsy, we have recently found a significantly increased prevalence of myocarditis in patients aged 18–45 years among consecutive patients hospitalized in medical wards for COVID-19 [30].

By comparison, multimodality imaging is of value in this situation, to confirm the diagnostic suspicion and to stratify patient risk (e.g. development of heart failure or life-threatening ventricular arrhythmias) [31]. As mentioned in the American Society of Echocardiography/European Association for Cardiovascular Imaging recommendations in the COVID-19 context, echocardiography remains the first-line examination to be used – not in routine clinical practice, but only in case of diagnostic suspicion [32,33]; it depicts several ranges of left ventricular (LV) systolic dysfunction and kinetic abnormalities [34]. Then, CMR allows more precise tissue characterization, enabling a positive diagnosis with, typically, LV dysfunction, myocardial edema and subepicardial left gadolinium enhancement in case of fibrotic scar [16,34].

Pioneering work from Puntmann et al. alerted the cardiovascular community to the possible high prevalence of myocarditis during COVID-19 [35]. One hundred patients, recently recovered from COVID-19 in one center in Germany, were studied by CMR, and were compared with 50 age- and sex-matched healthy volunteers. The huge proportions of 78% of patients with cardiac involvement and 60% with myocardial inflammation highlighted the need for systematic investigation of the long-term cardiovascular consequences of COVID-19. However, these results should be interpreted with caution, given the definitions of cardiac abnormalities used in this study, their uncertain clinical significance and some statistical issues [36]. More recently, a robust study compared 74 patients with COVID-19, 6 months after infection, with 75 age-, sex- and ethnicity-matched control subjects, and did not find any differences in cardiac structure, function or tissue characterization by CMR [37].

As far as we know, no studies have compared the prognosis of COVID-19-associated myocarditis with that of other myocarditis. Interestingly, Huang et al. showed that more than half of patients who recovered from COVID-19 had abnormal CMR findings, such as myocardial edema and fibrosis, although suspicion of myocarditis was not raised [4]. Further studies with prospective follow-up will be needed to answer this question. Nevertheless, in the majority of cases, under appropriate medical therapy (i.e. beta-blockers and angiotensin-converting enzyme inhibitors), progressive LV systolic recovery is achieved [34].

3. Secondary cardiac involvement

Probably much more frequent than primary cardiac involvement, secondary cardiac involvement is related to indirect heart damage occurring during COVID-19. This entity can take on many forms,
including myocardial injury, type I or II myocardial infarction (MI), sudden cardiac death, atrial fibrillation (AF), inflammatory myocarditis, acute pulmonary embolism or right ventricular (RV) failure.

3.1. Myocardial injury

According to the most recent universal definition of MI, the term myocardial injury should be used when there is evidence of elevated cardiac troponin values, at least above the 99th percentile of the upper reference limit [38]. This complication was described at the beginning of the pandemic in several studies of COVID-19 with very different levels of severity [1,3,4,39–50]. In a large cohort study, including 2736 patients hospitalized with COVID-19 with a troponin measurement within the first 24 h of admission, Lala et al. showed that myocardial injury was common (in about 36% of patients). Furthermore, the higher the troponin concentration at admission, the higher the risk of all-cause death, including for patients without previous cardiovascular disease and/or risk factors [46]. Sandová et al. showed that the frequency of myocardial injury increases with the severity of illness, ranging from 1% in COVID-19 survivors to 100% among the most severe forms. Moreover, patients with myocardial injury have a higher risk of acute respiratory distress syndrome, ventricular fibrillation and tachycardia [51]. A meta-analysis including more than 6000 patients found a prevalence of myocardial injury in COVID-19 ranging from 15% to 42% according to age and disease severity [52]; myocardial injury was again associated with all-cause mortality.

All of these elements highlight the value of troponin measurement for stratifying the risk of progression to a severe COVID-19 form, helping physicians with decision making when efficient triage is crucial (Table 2). Several mechanisms can explain myocardial injury, including inflammation and cytokine storm, prothrombotic and procoagulant state, imbalance between supply and oxygen demand (i.e. critical illness, sepsis, acute respiratory failure) and direct viral toxicity [46,50]. It is important to emphasize that patients with myocardial injury do not require specific treatment except for their underlying conditions. Finally, even if prognostic significance of troponin increase has been highlighted, troponin on its own is not always relevant. Indeed, it must be always interpreted considering cardiovascular risk factors, comorbidities and above all clinical data.

3.2. MI and acute coronary syndrome

When there is clinical evidence of acute ischemic myocardial injury, the term MI should be used [38]. Type 1 MI (i.e. secondary to acute atherosclerosis plaque disruption) must be separated from type 2 MI, related to imbalance between oxygen demand and supply with no involvement of coronary atherothrombosis [38]. In a retrospective Italian cohort, Stefani et al. showed that ST-segment elevation MI (STEMI) could be the first manifestation of COVID-19. In their study, 24 of 28 patients did not have a positive COVID-19 test before angiography [53]. In another study, Rodriguez-Leor et al. highlighted that patients with STEMI secondary to COVID-19 more frequently had acute heart failure at admission (P < 0.001) and increased in-hospital mortality (odds ratio 4.85, 95% confidence interval 2.04–11.51; P < 0.001) even after adjustment [54].

We should also mention that the first lockdown had a major impact on the incidence of MI. Indeed, several English, Italian and French studies emphasized a significant decrease in hospital admissions for both STEMI and non-STEMI, ranging from 12% to 40%, followed by an increase in out-of-hospital sudden cardiac death and long-term complications, such as heart failure [55–59]. This led to the writing of a position statement from the Society for Cardiovascular Angiography and Interventions, the American College of Cardiology and the American College of Emergency Physicians concerning the management of acute MI during the COVID-19 pandemic [60].

Finally, several cases of Takotsubo syndrome have been reported in the COVID-19 context [20,61,62]. This entity is classed as an MI with non-obstructive coronary arteries (MINOCA), implemented in the European guidelines in 2020 [63]. Takotsubo syndrome is acute reversible heart failure caused by acute severe stress, leading to sudden surges of catecholamines, which result in myocardial sideration and infarction. Although the prognosis of Takotsubo syndrome is generally good, with ad integrum recovery of LV function, there are no specific studies on Takotsubo prognosis in the context of COVID-19.

3.3. Arrhythmias

A direct consequence of both myocardial injury and MI, and the drop in in-hospital admissions for MI during the COVID-19 pandemic, was the increase in malignant arrhythmias (ventricular tachycardia and/or fibrillation) leading to sudden cardiac death. This is all the more true if there is an underlying arrhythmogenic substrate, such as ischemic cardiomyopathy [64], associated with a cytokine storm that acts as a trigger, and added to this a sympathetic hyperactivation, as can be encountered in the COVID-19 context, thus meeting the definition of the “Coumel triangle”, which is necessary for the genesis of an arrhythmia.

Several studies have warned public health authorities about the significant increase in out-of-hospital cardiac arrests (OHCA) during the COVID-19 pandemic and lockdown. Marjoni et al. showed that the maximum weekly rate of OHCA in Paris was twice as high as during the same period before the pandemic (13.42 to 26.64% per million inhabitants), and Lai et al. found that the rate was three times higher in New York City [65,66]. These two studies found a significant increase in OHCA at home, with less bystander cardiopulmonary resuscitation and shockable rhythm, longer delays to intervention and lower survival rates at hospital admission. Although sudden cardiac deaths are related not only to COVID-19 infection, but also to underlying conditions (i.e. cardiovascular risk factors, ischemic and non-ischemic cardiomyopathy) coupled with the indirect effect of lockdown, Baldi et al., from Northern Italy, showed that incidence of OHCA was associated with the cumulative incidence of COVID-19 [67]. Turagam et al. showed that malignant arrhythmia was not common (5%) among patients hospitalized with COVID-19, but was significantly more frequent among patients who died from COVID-19 [68].

AF is the most frequent arrhythmia encountered nowadays [69]. In the COVID-19 context, AF was also highlighted as one of the most frequent comorbidities among hospitalized patients, ranging from 14.6% in the Critical COVID-19 France study [70] to 36% in a cohort from Northern Italy [71]. Musikantow et al. found a new-onset AF incidence rate of 4%, leading to a debate about whether AF should be considered as a “simple bystander” or a real risk factor for worse prognosis [72,73]. In a meta-analysis of 31 studies, Romiti et al. showed that AF during COVID-19 was associated with an increased risk of all-cause mortality (odds ratio 3.97, 95% confidence interval 2.76–5.71), which was consistent among patients with new-onset AF [74].

3.4. Venous thromboembolic complications

Another form of secondary cardiovascular involvement in the COVID-19 context is represented by venous thromboembolic complications and pulmonary embolism (PE). At the very beginning of the pandemic, and driven by the possibility of a proinflammatory state, with abnormal hemostasis, endothelial dysfunction, disseminated intravascular coagulation and a proinflammatory response caused by COVID-19 [75–77], several reports indicated a higher PE prevalence in the COVID-19 context than is usually encountered in non-infected critically ill patients [78–83]. In a meta-analysis, Suh et al. showed that, among 27 seven studies that included 3342 patients with
COVID-19, the incidence rate of PE was 16.5% and of deep vein thrombosis was 14.8% [84]. The Critical COVID-19 France study identified independent risk factors associated with the occurrence of PE, which did not include traditional thromboembolic risk factors, but rather a proinflammatory and coagulopathy state in the COVID-19 context, such as male sex, elevated C-reactive protein and time from symptom onset to hospitalization. By comparison, anticoagulation with a therapeutic dose before admission or anticoagulation with a prophylactic dose during hospitalization were PE protective factors [85]. PE pathophysiology in the COVID-19 context, as well as the possibility of chronic thromboembolic pulmonary hypertension as a result of COVID-19 will be addressed in another review.

3.5. Right heart involvement

As a direct consequence of both pulmonary vascular disease (e.g. pulmonary embolism, endothelial dysfunction) and parenchymal lung involvement, right heart failure also appears to be a major form of secondary cardiac involvement in the COVID-19 context. This reflects a maladaptation between the right heart and the pulmonary vascular tree, which can be worse if RV dysfunction was present before the infection, secondary to left heart disease and/or pulmonary hypertension. Several echocardiographic studies have demonstrated that right heart dysfunction is common among patients with COVID-19. Szekely et al. showed that RV dilatation and dysfunction was present in 39% of those with COVID-19 [86], which is in line with other studies [87–90]. Further, RV dilatation and dysfunction have also been identified as independent prognostic factors among patients with COVID-19 [88,90]. Thus, and even if the echocardiography is not be performed systematically [91], in addition to the frequently used clinical and/or biological prognostic variables mentioned below, physicians must be aware that RV dysfunction and/or dilatation can also be useful to identify patients at high risk (i.e. of death and/or transfer to an intensive care unit).

4. Worsening of previous cardiovascular diseases

4.1. Chronic heart failure

Chronic heart failure (CHF) has rapidly emerged as one of the most important comorbidities among patients with COVID-19. Pagnides et al [10], from The Critical COVID-19 France study, found that 317 of 2809 hospitalized patients (11.3%) had a history of CHF, which is consistent with the study by Alvarez-Garcia et al [9]. Among more than 30,000 patients with a pre-existing CHF diagnosis, Rumery et al. showed that a positive COVID-19 reverse transcription polymerase chain reaction (RT-PCR) was associated with a 30-day hospital admission rate of 27% and a 30-day mortality rate of 37%, irrespective of age, sex, cardiovascular risk factors and comorbidities [92]; this was also found in other studies [8,10,93,94]. Another interesting finding from these studies was that survival in patients with COVID-19 was not driven by LV ejection fraction [9,10], which should prompt physicians to consider CHF history as being associated with death, regardless of the ejection fraction. This lack of LV ejection fraction effect may be explained by the fact that heart failure with preserved ejection fraction is, by nature, associated with several comorbidities and cardiovascular risk factors, such as hypertension and diabetes, which are also implicated in COVID-19 prognosis. In addition, CHF was also associated with significant two- and three-fold increases in the risk of intensive care unit transfer and intubation, respectively [9]. Experience with concentrations of natriuretic peptides (brain natriuretic peptide and N-terminal prohormone of brain-natriuretic peptide) in the COVID-19 context remains limited, yet the levels of these biomarkers seem to be correlated with disease severity and mortality, leading the European Society of Cardiology to recommend their assessment whenever heart failure is suspected [95].

Tomasoni et al. showed that CHF had a severe impact on clinical course among patients hospitalized with COVID-19, as it was significantly associated with an increased risk of acute heart failure, sepsis, acute kidney injury and multiorgan failure compared with controls, yet significantly less pulmonary embolism, probably related to a higher curative anticoagulation rate at admission [96].

At the start of the pandemic, several studies warned public health authorities about the interaction between angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers and COVID-19 severity [13,97,98]. Indeed, knowing that SARS-CoV-2 enters cells (primarily type II pneumocytes) by binding to its functional receptor, ACE2, it was hypothesized that inhibition of angiotensin-converting enzyme would upregulate ACE2, increasing SARS-CoV-2 entry into the organism and thus lung damage. Therefore, it was unclear whether to suspend these treatments in case of COVID-19. The BRACE-CORONA randomized control trial answered this question, showing that there were no statistical differences concerning length of hospital stay and all-cause mortality [99]. Nevertheless, very few patients with CHF were enrolled in this study (<2%), but Rey et al, in a retrospective study, showed that discontinuation of heart failure drugs (i.e. beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptors blockers, mineralocorticoid receptor antagonists) was associated with a higher rate of all-cause mortality [94]. Like other cardiovascular manifestations mentioned above, the first COVID-19 wave was associated with a decrease in hospitalization for acute heart failure, ranging from ~30% to ~60%, followed by a significant increase in mortality (~60%) following the first lockdown [100,101].

All of these data should encourage physicians to detect patients with heart failure early during COVID-19 hospitalizations, not to discontinue CHF drugs and to readress patients to their attending cardiologist upon discharge.

4.2. Cardiovascular risk factors

Another main characteristic of patients hospitalized with COVID-19 is a high prevalence of cardiovascular risk factors. In a multicenter French study, Bonnet et al [70], found that hypertension was found in half of patients (50.8%) and obesity in 30% of cases, whereas diabetes and dyslipidemia were present in about one quarter of patients (23.7% and 28%, respectively), and 13.5% of the cohort were smokers, which is consistent with other reports [1,4,102–104]. Diabetes, obesity and hypertension seem to be associated with worse COVID-19 forms and outcomes (i.e. in-hospital death, intensive care unit transfer and/or need for mechanical ventilation) [105–110]. However, contradictory data exist concerning smoking habits [111–113]. We recently showed that young patients aged 18–45 years were less likely to present the composite of in-hospital death or intensive care unit transfer during COVID-19 compared with older patients [30], concordant with previous reports observing that old age is a strong risk factor for worse prognosis [114]. However, our analysis found a particular effect of COVID-19 on cardiovascular outcomes in young patients, with an increased prevalence of myocarditis and pericarditis, although thrombotic complications occurred with a similar incidence to that in older patients. Finally, Weizman et al. showed that although female sex was associated with a lower risk of intensive care unit transfer, the presence of pre-existing cardiovascular risk factors and disease among women was associated with higher morbidity [115].

It is therefore difficult to evaluate the impact of COVID-19 on the decompensation of these diseases because, to our knowledge, no study has specifically answered this question (unlike for heart failure and MI). Nevertheless, physicians must be attentive to treatment after hospitalization discharge, and encourage patients to resume specialized care to avoid a post-pandemic recrudescence of
cardiovascular fatal events (i.e. acute heart failure, MI, stroke and sudden cardiac death).

5. Beyond the acute phase of COVID-19

5.1. Long-term effects of SARS-CoV-2 infection

Viral infections are known to have the potential to cause chronic cardiovascular effects. Previous data on severe acute respiratory syndrome coronavirus 1 suggested a worse cardiovascular prognosis after infection, and altered lipid metabolism [116]. Similarly, emergency department visits for influenza-like illness were correlated with cardiovascular disease mortality [117]. After the acute phase of COVID-19, a constellation of persistent symptoms, including cardiovascular symptoms, could persist [118,119]. Whereas dyspnea is the most frequent persistent symptom of a probable multifactorial etiology [118,120,121], chest pain is frequently reported long term after the acute phase of COVID-19; its prevalence is approximately 20% at 60 days after a moderate-to-severe form of the disease [118,122], and 5% at 6 months [120]. This frequent symptom echoes the different CMR abnormalities observed after the acute COVID-19 phase, as mentioned previously. However, the determinants and mechanisms of persistent chest pain remain incompletely understood, and future investigations will be required. Palpitations were also common, with a prevalence of 14% at 60 days [122] and 9% at 6 months [120]. In parallel, electrocardiographic changes and arrhythmias were observed via systematic screening in approximately one third of patients after a non-severe form of COVID-19 [123]. Finally, COVID-19 infection may have a long-term impact, with: (1) possible long-term sequelae of acute cardiovascular complications, such as pulmonary embolism, acute MI or myocarditis; (2) the disruption of routine follow-up of chronic cardiac conditions induced by the pandemic; and (3) persistent aforementioned symptoms, the mechanisms, prognosis and psychological impact of which are not well known.

Recently, Xie et al. reported the long-term cardiovascular outcomes of COVID-19 [124]. Studying a population of 153,760 COVID-19 patients (non-hospitalized, hospitalized and admitted to intensive care unit) compared to two sets of control patients including more than 10 millions of individuals, they found that: i) there was a significant 12-months increased of ischemic and non-ischemic heart disease, heart failure, thromboembolic events, cerebrovascular disorders, pericarditis and myocarditis, ii) this risk was consistent among non-hospitalized patients and higher according to the care setting during the acute COVID-19 phase. These results highlight the importance of close cardiovascular follow-up at least during the year following a COVID-19 but also of preventive messages that physicians should spread more widely to the population.

5.2. Cardiovascular complications of COVID-19 vaccines

Several cardiovascular complications have been associated with COVID-19 vaccination. The issue of myocarditis or pericarditis after a COVID-19 vaccine has been raised in several case reports after messenger ribonucleic acid (mRNA) vaccines (Pfizer-BioNTech and Moderna) [125–127]. Although it is difficult to estimate its precise prevalence, this complication seems to be uncommon [128,129], and is associated with favorable outcomes and recovery [130]. The most important study to date was based on surveillance data from the nationwide vaccination campaign in Israel, involving more than five million individuals [131]. The authors observed 136 cases of definite or probable myocarditis occurring in temporal proximity to two doses of the BNT162b2 mRNA vaccine (Pfizer-BioNTech). The risk of myocarditis seems to be higher among those aged 16–19 years, with a prevalence of approximately 1 in 6,637 of this population. In another large study derived from an Israeli population with at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons, with a higher prevalence among males aged 16–29 years, and a majority of cases of mild or moderate severity [129]. The mechanism of vaccine-induced myocarditis is not completely understood, but may be related to the immune response after vaccination, to the active component of the vaccine or to the mRNA sequence coding for the SARS-CoV-2 spike protein.

In addition to myocarditis, previous studies have suggested that SARS-CoV-2 vaccines with an adenovirus vector, including the ChAdOx1 nCoV-19 vaccine (AstraZeneca), may cause thrombotic thrombocytopenia and subsequent thromboembolic complications [132,133]. A previous study showed a 1.97-fold increased risk of thromboembolic events among individuals who received the AstraZeneca vaccine compared with the general population [134]. The pathophysiology of this complication includes, at least in part, the generation of anti-PF4 antibodies, which activate platelets via specific receptors, an established mechanism also observed in heparin-induced thrombocytopenia [135]. Vaccine-induced immune thrombotic thrombocytopenia consists of venous or arterial thrombosis in atypical sites, such as cerebral sinus venous thrombosis, associated with mild-to-severe thrombocytopenia occurring a few days after the ChAdOx1 nCoV-19 vaccine.

Other COVID-19 vaccine side effects have been suspected, with an unclear causal relationship or very rare incidence: arrhythmia [136]; MI [137,138]; Takotsubo cardiomyopathy [139,140]; and systemic hypertension [141,142].

6. Conclusion

In this review, we have depicted the cardiovascular consequences of COVID-19; whether they are related to primary myocardial involvement, secondary myocardial involvement or decompensation of a pre-existing cardiovascular disease, they are always associated with a worse prognosis (Graphical abstract). Physicians need to be aware that beyond pulmonary damage, cardiovascular involvement must be sought out and treated. This pandemic continues to progress in successive waves of varying intensity with different variants. Further studies are required to fully understand the cardiovascular impact of COVID-19 during the acute phase and long term, and to describe the potential specific cardiovascular impact of some variants.

Funding

None.

Declaration of Competing Interest

The authors declare that they have no conflicts of interest concerning this article. Dr Fauvel reports grants from Pfizer and consulting fees from Janssen, outside the submitted work. Prof Cohen acknowledges the following without any relationship to the current manuscript: research grant from RESICARD (research nurses); and consultant and lecture fees from the companies Amgen, AstraZeneca, Bayer Pharma, Alliance BMS- Pfizer, Novartis, and Sanofi-Aventis.

References

[1] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10.
[2] World Health Organization. Coronavirus disease (COVID-19) outbreak [https://www.who.int].
[3] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8(5):475–81.
COVID-19: JACC scientific expert panel. J. Am. Coll. Cardiol. 2020;76(11):1345–57.

Kirkpatrick JN, Mitchell C, Taub C, Kort S, Hung J. Swaminathan M. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak: endorsed by the American College of Cardiology, J. Am. Soc. Echocardiogr. 2020;33(6):648–53.

Skulstad H, Cosynos B, Popescu BA, Galders M, Salvo GD, Donal E, et al. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, and categorization, and protection for patients and healthcare personnel. Eur. Heart J. Cardiovasc. Imaging 2020;21(6):592–8.

Aglicola E, Beneduce A, Esposito A, Inaglia G, Palumbo D, Palmisano A, et al. Heart and lung multimodality imaging in COVID-19. JACC Cardiovasc. Imaging. 2020;13(8):1792–808.

Puntmann VO, Carell MJ, Wieters I, Fahmin M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA 2020;5(11):1307–17.

Joy G, Artico J, Kurhi H, Seraphim A, Lau C, Thornton GD, et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Imaging. 2021;4(11):1556–65.

Thygesen K, Alpert JS, Jaffe AS, Chair H, Morris DA, et al. Fourth universal definition of myocardial infarction (2018). Eur. Heart J. 2019;40(9):3:273–69.

Arentz M, Yim E, Klafl L, Lohmandalwa S, Riedo F, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;323(16):1612–4.

Bhatraju PK, Chassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. COVID-19 in critically ill patients in the Seattle region - case series. N. Engl. J. Med. 2020;382(17):1645–52.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1991.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of COVID-19. J. Am. Coll. Cardiol. 2020;76(20):2334–48.

Panagides V, Vincent F, Weizman O, Jonveaux M, Trimaille A, Pommier T, et al. Pathological findings of COVID-19 associated multivisceral involvement in a patient with coronavirus disease 2019. Insights from a French registry. Arch. Cardiovasc. Dis. 2021;114(5):415–25.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323(20):2052–9.

Nishiga M, Wang DW, Han Y, Lewis DB, Wu J. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17(9):543–67.

Vadivelathan M, Vardeny G, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N. Engl. J. Med. 2020;382(17):1653–9.

Clerkin KJ, Fried JA, Rakheilkar J, Sayer G, Griffin JM, Masoumi A, et al. Cardiovascular and respiratory outcomes in COVID-19 patients: a systematic review and meta-analysis. Circulation 2020;141(21):2122–37.

Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet 2020;396(10247):30–22.

Garlo J, Amour P, Peretz T, Dermond F, Mesouda K, Profet M, et al. SARS-CoV-2 fulminant myocarditis. JACC Case Rep. 2020;2(9):1342–6.

Kim IC, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur. Heart J. 2020;41(19):1859.

Lauer VS, Wu AH, Gani R,emblement J, Satterman N, Nattermann J, Sprinkart AM, et al. Diffuse myocardial inflammation in COVID-19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging. Circ Cardiovasc. Imaging. 2020(35):1–8.

Paul JF, Charles P, Richard C, Guisdon C, Diallo C. Myocarditis revealing COVID-19 infection in a young patient. Eur. Heart J. Cardiovasc. Imaging 2020;21(7):776.

Sala S, Peretto G, Gramegna M, Palmisano A, Villarolle A, Vignale D, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur. Heart J. 2020;41(19):1861–2.

Tavaazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. Heart J. 2020;22(5):911–5.

Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial involvement in a patient with coronavirus disease 2019. JACC Case Rep. 2020;2(9):1342–6.

Caforio ALP, Pankweert S, Arbustini E, Basso C, Cimmino-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of cardiology working group on myocardial and pericardial diseases. Eur. Heart J. 2011;32(31):2648a–9d.

Lindner D, Fitzke A, Brauninger H, Alecscheva G, Edler C, Meissner K, et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 2020;5(11):1281–8.

Fox SE, Li G, Akhtembekov A, Harbert JL, Lameire FS, Brown JQ, et al. Unexpected features of cardiac pathology in COVID-19 infection. Circulation 2020;142(11);1123–5.

Kawakami R, Sakamoto A, Kawai K, Gianatti A, Pellegrini D, Naas A, et al. Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week. J. Am. Coll. Cardiol. 2021;77(3):314–25.

Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc. Pathol. 2021;50:107300.

Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American heart association, the American college of cardiologists, and the European Society of cardiology endorsed by the heart failure society of America and the heart failure association of the European society of cardiology. J. Am. Coll. Cardiol. 2021;190805.

Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis associated with influenza A H1N1pdm09. Influenza Res. Treat. 2012;2012:351979.

Trimaille A, Ribeyrolles S, Fauvel C, Chaumont C, Weizman O, Pommier T, et al. Cardiovascular characteristics and outcomes of young patients with COVID-19. Cardiovasc. Dev. Dis. 2021;8(12):165.

Rudski L, Januzzi JL, Rigolin VH, Bohula EA, Blankstein R, Patel AR, et al. Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC scientific expert panel. J. Am. Coll. Cardiol. 2020;76(11):1345–57.
regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health 2020;5(10):e536–42.

[59] Rangi C, Hakim R, Beygui F, Angovska V, Marcellot P, Codin M, et al. Incidence, delays, and outcomes of STEMI during COVID-19 outbreak: analysis from the France PCI registry. Emerg. Med. J. 2020;27(10):620–6.

[60] Mahmoud E, Dauerman HL, Weit RGP, Messenger JC, Rau SV, Grimes C, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a position statement from the Society for Cardiovascular Angiography and Interventions (SCAI). The American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J. Am. Coll. Cardiol. 2020;76(11):1375–84.

[61] Magnani P, Depravoux S, Van Delden C, Ghadri JR, Templin C. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur. Heart J. 2020;41(19):1860.

[62] Ortuño S, Jozwiak M, Mira JP, Nguyen LS. Case report: takotsubo syndrome associated with novel coronavirus disease 2019. Front. Cardiovasc. Med. 2020;7:136.

[63] Collet JP, Thiele H, Barbato E, Bartholimi O, Bausersch J, Bhatt DL, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021;42(14):1289–367.

[64] Mitacchione G, Schiavone M, Gasperetti A, Forleo GB. Ventricular tachycardia associations with D-Dimer levels. Radiology 2020;23:201561.

[65] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146714/.

[66] COVID-19. Thromb. Res. 2020;191:145 –70.

[67] Sanchis-Gomar F, Perez-Quilis C, Lavie CJ. Should atrial fibrillation be considered during the COVID-19 pandemic in Paris, France: a population-based, observational study. Lancet Public Health 2020;5(8):e437–43.

[68] Baldi E, Sechi GM, Mare C, Canevari F, Brangiacupe A, Primi R, et al. Out-of-hospital cardiac arrest during the covid-19 outbreak in Italy. N. Engl. J. Med. 2020;383(5):496–8.

[69] Turagam MK, Musikantov D, Goldman ME, Bassily-Marcus A, Chu E, Shvamurthy P, et al. Malignant arrhythmias in patients with COVID-19: incidence, mechanisms, and outcomes. Circ. Arrhythm. Electrophysiol. 2020;13(11):e008920.

[70] Hindricks G, Potpara T, Dages N, Arbelo E, Bar J, Blomström-Lundqvist C, et al. The 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42(1):47–98.

[71] Bonnet G, Weizman O, Trimaille A, Pommier T, Cellier J, Geneist L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 in France: the critical COVID-19 France (CCF) study. Arch. Cardiovasc. Dis. 2021;114(5):352–63.

[72] Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur. Heart J. 2020;41(19):1821–9.

[73] Inciardi RM, Adamo M, Lupi L, Metra M. Atrial fibrillation in the COVID-19 era: simple bystander or driver of increased risk? Eur. Heart J. 2020;41(32):3092–3.

[74] Sanches-Gomar F, Perez-Quirico C, Lavie CJ. Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients? Eur. Heart J. 2020;41(32):3092–3.

[75] Romiti GF, Corica B, Lip GYH, Proietti M. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 2021;8(3):1033–58.

[76] Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni A, Pieri M, et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the covid-Italy multicentre study. Eur. J. Heart Fail. 2020;22(12):2238–47.

[77] G.M. Kuster, O. Pinto, T. Marzola, D. vonfro, L. Haefeli, et al. Coronary calcium score in COVID-19: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2021;78:5097–100.

[78] Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Macedo AVS, et al. SARS-CoV-2 infection. Eur. Heart J. 2020;41(19):1860.

[79] G.M. Kuster, O. Pinto, T. Marzola, D. vonfro, L. Haefeli, et al. Coronary calcium score in COVID-19: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2021;78:5097–100.

[80] G.M. Kuster, O. Pinto, T. Marzola, D. vonfro, L. Haefeli, et al. Coronary calcium score in COVID-19: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2021;78:5097–100.

[81] Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA 2020;323:769–70.

[82] G.M. Kuster, O. Pinto, T. Marzola, D. vonfro, L. Haefeli, et al. Coronary calcium score in COVID-19: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2021;78:5097–100.
analyses from a French retrospective cohort. Diabetes Metab. 2021;47(4):101222.

[109] Wei ZY, Qiao R, Chen J, Huang J, Wu H, Wang WJ, et al. The influence of pre-existing hypertension on coronavirus disease 2019 patients. Epidemiol. Infect. 2021;149:e4.

[110] Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol. Infect. 2020;148:e106.

[111] Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 2020;55(5):2000688.

[112] Lutchman D. Could the smoking gun in the fight against COVID-19 be the (rh) ACE-2? Eur. Respir. J. 2020;56(1):2001560.

[113] Rossato M, Russo L, Mazucchelli D, Di Vincenzo A, Fiorotto P, Vettor R. Current smoking is not associated with COVID-19. Eur. Respir. J. 2020;55(6):2001290.

[114] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.

[115] Weizman O, Mika D, Cellier J, Geneste L, Trimaille A, Pommier T, et al. Characteristics and impact of cardiovascular comorbidities on coronavirus disease 2019 in women: a multicentre cohort study. Arch. Cardiovasc. Dis. 2021;114(5):394–406.

[116] Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci. Rep. 2017;7(1):9110.

[117] Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol. 2016;1(3):274–81.

[118] Caffi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603–5.

[119] Logue JR, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelea in adults at 6 months after COVID-19 infection. JAMA Netw. Open 2021;4(2):e210830.

[120] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of symptom onset. Clin. Microbiol. Infect. 2021;27(2):258–63.

[121] Zhou M, Won CK, Un KC, Lau YM, Lee JCY, Tam FCC, et al. Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS ONE 2021;16(2):e0246732.

[122] Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583–90.

[123] Matta A, Kallamadi R, Matta D, Bande D. Post-mRNA COVID-19 vaccination myocarditis. Eur. J. Case Rep. Intern. Med. 2021;8(8):002769.

[124] Tailor PD, Feighery AM, El-Sabawi B, Prasad A. Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur. Heart J. Case Rep. 2021;5(8):ytya319.

[125] Visčlošky T, Theyynnī N, Kličkovskī N, Bradinī S. Myocarditis following mRNA COVID-19 vaccine. Pediatr. Emerg. Care 2021;37(11):583–4.

[126] Hajo R, Sallakhi DA, Bardaweel SK, Tropsa A. Shedding the light on post-vaccine myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients. Vaccines (Basel) 2021;9(10):1186.

[127] Vithag A, Barda N, Hoss S, Richter I, Wiessmann M, Asiv Y, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N. Engl. J. Med. 2021;385(23):2132–9.

[128] Shiyovich A, Vithag G, Asiv Y, Eisen A, Orvin K, Wiessman M, et al. Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur. Heart J. Cardiovasc. Imaging 2021;001–8.

[129] Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N. Engl. J. Med. 2021;385(23):2140–9.

[130] Gupta A, Sardar P, Cash MF, Milan RV, Lavie CJ. COVID-19 vaccine–induced thrombosis and thrombocytopenia—a commentary on an important and practical clinical dilemma. Prog. Cardiovasc. Dis. 2021;67:105–7.

[131] Sadoff J, Davis K, Dougash M. Thrombocytic thrombocytopenia after Ad26.COV2.S vaccination − response from the manufacturer. N. Engl. J. Med. 2021;384(20):1965–6.

[132] Pottegard A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study. BMJ 2021;373:n1114.

[133] Marchandt B, Carmona A, Trimaille A, Curtiaud A, Morel O. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis. J. Thromb. Thrombolysis 2021;52(3):689–91.

[134] Reddy S, Reddy S, Arora M. A case of postural orthostatic tachycardia syndrome secondary to the messenger RNA COVID-19 vaccine. Cureus 2021;13(5):e14837.

[135] Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal? Diabetes Metab. Syndr. 2021;15(3):1055–6.

[136] Tajstra M, Jaroszewicz J, Gasior M. Acute coronary artery thrombosis after vaccination for COVID-19: JACC Cardiovasc. Interv. 2021;14(9):e103–4.

[137] Crane P, Wong C, Mehta N, Barlis P. Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination. BMJ Case Rep. 2021;14(10):e246580.

[138] Jani C, Leavitt J, Al Omari O, Dimaso A, Pond K, Gannon S, et al. COVID-19 vaccine-associated Takotsubo cardiomyopathy. Am. J. Ther. 2021;28(3):361–4.

[139] Meylan S, Livio F, Forester M, Genoud PJ, Margaret F, Wuerzner G, et al. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension 2021;77(6):e56–7.

[140] Zappa M, Verdeccia P, Spanevello A, Visca D, Angeli F. Blood pressure increase following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur. J. Intern. Med. 2021:90:111–3.